NCCTG to Conduct Phase II Study of Cell Therapeutics' Brostallicin in Metastatic Triple Negative Breast Cancer

News   Apr 29, 2010

 
NCCTG to Conduct Phase II Study of Cell Therapeutics' Brostallicin in Metastatic Triple Negative Breast Cancer
 
 
 

RELATED ARTICLES

Antimalarial Drugs Could Offer Clinical Benefit to Cancer Patients

News

Antimalarial drugs chloroquine and hydroxychloroquine could find another use as cancer treatments, according to a new clinical study published in ecancermedicalscience.

READ MORE

Dipstick Technology Enables Rapid Diagnosis Anywhere

News

A new Australian study has reported a revolutionary dipstick technology that allows DNA and RNA to be extracted from living organisms in as little as 30 seconds.

READ MORE

Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line Treatment

News

The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Diagnostics Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE